162 related articles for article (PubMed ID: 38451188)
21. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
22. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
23. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
24. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD.
Shi T; Hu Z; Tian L; Yang Y
Respir Res; 2023 Apr; 24(1):113. PubMed ID: 37061713
[TBL] [Abstract][Full Text] [Related]
25. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
26. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors.
Zhu M; Wang X; Zhang Q; Xie C; Wang T; Shen K; Zhang L; Zhou X
Aging (Albany NY); 2024 Feb; 16(3):2563-2590. PubMed ID: 38315450
[TBL] [Abstract][Full Text] [Related]
29. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
31. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
32. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
33. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of PSME3: from pan-cancer analysis to experimental validation.
Dong C; Guo Y; Yang Y; Ge X
Front Immunol; 2024; 15():1295693. PubMed ID: 38312840
[TBL] [Abstract][Full Text] [Related]
35. Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
Li H; Sun X; Zhao Y; Zhang C; Jiang K; Ren J; Xing L; He M
BMC Cancer; 2023 Jun; 23(1):528. PubMed ID: 37296415
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
37. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.
Zhang D; Jiang Z; Hu J; Sun X; Zheng Y; Shen Y
Front Immunol; 2023; 14():1117585. PubMed ID: 37251370
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and immune infiltrative biomarkers of CENPO in pan-cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis.
Wang Y; Ye D; Li Y; Lv F; Shen W; Li H; Tian L; Fan Z; Li Y; Wang Y; Li F; Chen Y
BMC Cancer; 2023 Aug; 23(1):735. PubMed ID: 37558987
[TBL] [Abstract][Full Text] [Related]
39. Prediction of prognosis and immunotherapy response in lung adenocarcinoma based on CD79A, DKK1 and VEGFC.
Zhang Q; Zhao M; Lin S; Han Q; Ye H; Peng F; Li L
Heliyon; 2023 Aug; 9(8):e18503. PubMed ID: 37534013
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.
Wei Q; Miao T; Zhang P; Jiang B; Yan H
Front Genet; 2022; 13():984575. PubMed ID: 36159963
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
